A Multicenter, Randomized, Double-blind, Four-Arm Parallel-Group, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Icotinib (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd
- 09 Nov 2018 Status changed from recruiting to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 17 Dec 2017 Status changed from not yet recruiting to recruiting.